Avalon GloboCare Expands IP Portfolio; Files 16 New Patent Applications
April 27, 2022 09:00 ET
|
Avalon GloboCare Corp.
Co-inventors are leading international universities and cellular therapy developers Patent applications cover three types of cellular therapies and related technologies FREEHOLD, N.J., April ...
Avalon GloboCare Expands its Cellular Immuno-Oncology Platform with the Addition of Novel Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapies
February 14, 2022 09:00 ET
|
Avalon GloboCare Corp.
Leveraging Avalon’s existing Flash-CARTM technology platform to develop next-generation mRNA-based CAR-NK cellular therapeuticsClinical development of CAR-NK cell therapy planned in collaboration with...
Avalon GloboCare Provides Year-End Business Update of Selective Scientific and Clinical Programs
January 04, 2022 09:00 ET
|
Avalon GloboCare Corp.
Company continues to expand and accelerate its R&D strategies for high-impact translational and clinical programs in the US and Europe Intended SenlangBio acquisition terminated, eliminating...
Avalon GloboCare’s Chairman Converts Debt into Common Stock at 45% Premium to Market
December 22, 2021 09:00 ET
|
Avalon GloboCare Corp.
FREEHOLD, N.J., Dec. 22, 2021 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO) (Avalon or The Company), a clinical-stage global developer of cell-based technologies and therapeutics, today...
Avalon GloboCare Advances AI-Enhanced Protein Design Technology for Cellular Therapy Development
December 09, 2021 09:00 ET
|
Avalon GloboCare Corp.
Avalon and research partner, Massachusetts Institute of Technology (MIT), combine their protein design “QTY Code” technology with Google’s DeepMind artificial intelligence (AI) program, AlphaFold2, to...
Avalon GloboCare Jointly Files US and International Patent Application for Breakthrough S-Layer Coated Emulsome Technology (SLET) for Next-Generation Drug Delivery and Cellular Immunotherapy
October 14, 2021 09:20 ET
|
Avalon GloboCare Corp.
Co-developed novel technology platform combining S-layer proteins and emulsomes for diverse applications in bio-delivery of drugs and genes with the University of Natural Resources and Life Sciences...
Avalon GloboCare and University of Natural Resources and Life Sciences (BOKU) Co-develop Innovative In-Silico Technology, Enabling the Design and Synthesis of Novel Cell Membrane Receptor Targets for Cancer and Immune-Related Diseases
October 07, 2021 09:00 ET
|
Avalon GloboCare Corp.
Avalon and research partner, University of Natural Resources and Life Sciences (BOKU), in Vienna, Austria, co-develop a novel technology to efficiently synthesize and study previously difficult to...
Avalon GloboCare to Present at the Benzinga Healthcare Small Cap Conference on September 30th
September 23, 2021 09:00 ET
|
Avalon GloboCare Corp.
FREEHOLD, N.J., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO) (Avalon or The Company), a clinical-stage global developer of cell-based technologies and therapeutics, today...
UPMC and Pitt Develop New Cancer Immunotherapy with Avalon GloboCare
August 04, 2021 09:00 ET
|
Avalon GloboCare Corp.
PITTSBURGH, Aug. 04, 2021 (GLOBE NEWSWIRE) -- A new collaboration among UPMC Hillman Cancer Center, the University of Pittsburgh and New Jersey-based biotechnology company Avalon GloboCare Corp....
Avalon GloboCare Announces its Planned Acquisition Target, SenlangBio, has Initiated First-In-Human Clinical Trial in Recurrent Brain Cancer
July 01, 2021 09:00 ET
|
Avalon GloboCare Corp.
Trial evaluating EphA2-targeted CAR T-cell therapy in recurrent glioblastoma, an urgent and significant unmet medical need with no standard of care treatment option Anti-EphA2 CAR-T therapy appears...